$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000117891313001073 Filed on April 11, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$500.0K	$510.0K	$230.0K
YoY Change	72.41%	121.74%	-25.81%
% of Gross Profit
Research & Development	$835.6K	$749.0K	$710.6K
YoY Change	234.59%	5.4%	108.2%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
% of Gross Profit
Operating Expenses	$835.6K	$749.0K	$710.6K
YoY Change	234.59%	5.4%	108.2%
Operating Profit	-$1.335M	-$1.260M	-$940.4K
YoY Change	146.97%	33.97%	45.29%
Interest Expense	$80.00K	$30.00K	$0.00
YoY Change	-900.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.256M	-$1.226M	-$985.4K
YoY Change	128.27%	24.41%	53.3%
Income Tax
% Of Pretax Income
Net Earnings	-$1.256M	-$1.226M	-$985.4K
YoY Change	128.27%	24.41%	53.3%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$174.5K	-$170.6K	-$169.2K
COMMON SHARES
Basic Shares Outstanding	7.223M shares		70.19M
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.230M	$5.340M	$3.000M
YoY Change	95.83%	78.0%	-19.14%
Cash & Equivalents	$1.105M	$2.040M	$1.824M
Short-Term Investments	$3.130M	$3.300M	$1.180M
Other Short-Term Assets	$80.00K	$60.00K	$30.00K
YoY Change	100.0%	100.0%	-25.0%
Inventory
Prepaid Expenses	$62.30K	$36.41K	$12.81K
Receivables	$333.7K	$439.8K	$46.67K
Other Receivables	$178.8K	$99.53K	$28.05K
Total Short-Term Assets	$4.824M	$5.939M	$3.108M
YoY Change	96.21%	91.08%	-19.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.730K	$1.869K	$7.792K
YoY Change	170.16%	-76.01%	-74.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	-66.67%
Other Assets	$10.00K	$10.00K	$20.00K
YoY Change		-50.0%
Total Long-Term Assets	$22.52K	$17.93K	$34.31K
YoY Change	42.62%	-47.73%	-31.39%
TOTAL ASSETS
Total Short-Term Assets	$4.824M	$5.939M	$3.108M
Total Long-Term Assets	$22.52K	$17.93K	$34.31K
Total Assets	$4.846M	$5.957M	$3.143M
YoY Change	95.87%	89.57%	-19.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$400.0K	$420.0K	$530.0K
YoY Change	29.03%	-20.75%	1.92%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$446.0K	$469.4K	$582.2K
YoY Change	25.34%	-19.37%	2.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$240.0K	$240.0K	$160.0K
YoY Change	60.0%	50.0%	0.0%
Total Long-Term Liabilities	$241.1K	$239.9K	$162.0K
YoY Change	64.17%	48.05%	1.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$446.0K	$469.4K	$582.2K
Total Long-Term Liabilities	$241.1K	$239.9K	$162.0K
Total Liabilities	$687.1K	$709.3K	$744.1K
YoY Change	36.68%	-4.68%	1.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.33M	-$20.08M	-$16.01M
YoY Change	28.81%	25.39%
Common Stock	$25.36M	$25.08M	$18.41M
YoY Change	36.95%	36.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.159M	$5.248M	$2.398M
YoY Change
Total Liabilities & Shareholders Equity	$4.846M	$5.957M	$3.143M
YoY Change	95.87%	89.57%	-19.21%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$1.256M	-$1.226M	-$985.4K
YoY Change	128.27%	24.41%	53.3%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Cash From Operating Activities	-$1.050M	-$1.280M	-$600.0K
YoY Change	19.32%	113.33%	200.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$110.0K	-$2.200M	$960.0K
YoY Change	-67.65%	-329.17%	-153.93%
Cash From Investing Activities	$110.0K	-$2.200M	$960.0K
YoY Change	-67.65%	-329.17%	-153.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-10.00K	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-1.050M	-1.280M	-600.0K
Cash From Investing Activities	110.0K	-2.200M	960.0K
Cash From Financing Activities	0.000	-10.00K	0.000
Net Change In Cash	-940.0K	-3.490M	360.0K
YoY Change	74.07%	-1069.44%	-56.63%
FREE CASH FLOW
Cash From Operating Activities	-$1.050M	-$1.280M	-$600.0K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$1.050M	-$1.280M	-$600.0K
YoY Change	19.32%	113.33%	200.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
CY2011	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3782	USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature	108000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-02-28
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001176309
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7222636	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	177782	USD
CY2008	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	203982	USD
CY2009	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	117174	USD
CY2010	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	116944	USD
CY2011	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	26733	USD
CY2012	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	70292	USD
	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	8437	USD
CY2008	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2009	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2010	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
	ormp	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetChangeInFairValue	172218	USD
	ormp	Imputed Interest Expense ImputedInterestExpense		USD
	ormp	Imputed Interest Expense ImputedInterestExpense		USD
	ormp	Imputed Interest Expense ImputedInterestExpense	23559	USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances	6061	USD
CY2013Q1	ormp	Purchase Obligations PurchaseObligations	424000	USD
CY2013Q1	ormp	Purchase Obligations PurchaseObligations	395000	CHF
CY2008	ormp	Receipts On Account Of Shares And Warrants ReceiptsOnAccountOfSharesAndWarrants	6061	USD
	ormp	Shares Cancelled Value SharesCancelledValue		USD
	ormp	Shares To Be Issued For Services Rendered SharesToBeIssuedForServicesRendered		USD
	ormp	Shares To Be Issued For Services Rendered SharesToBeIssuedForServicesRendered	30435	USD
	ormp	Shares To Be Issued For Services Rendered SharesToBeIssuedForServicesRendered		USD
	ormp	Stock Issued During Period Value Marketable Securities StockIssuedDuringPeriodValueMarketableSecurities	628630	USD
	ormp	Stock Issued During Period Value Offering Costs StockIssuedDuringPeriodValueOfferingCosts		USD
	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	98750	USD
CY2008	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	116110	USD
CY2009	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	152928	USD
CY2010	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	249850	USD
CY2011	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	227569	USD
CY2012	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	107860	USD
CY2009	ormp	Stock Issued During Period Value Services To Be Rendered StockIssuedDuringPeriodValueServicesToBeRendered	203699	USD
CY2012Q4	ormp	Warrants And Rights Expense Recognized WarrantsAndRightsExpenseRecognized	296982	USD
	ormp	Warrants Exchanged WarrantsExchanged	296982	USD
	ormp	Warrants Exchanged WarrantsExchanged		USD
	ormp	Warrants Exchanged WarrantsExchanged	296982	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	422142	USD
CY2012Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	597173	USD
CY2013Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2012Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	439753	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87691	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	244508	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	24993248	USD
CY2012Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	21589715	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18991	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1968547	USD
CY2008	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	459467	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	436025	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	690882	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	502593	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	200866	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	917809	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2013Q1	us-gaap	Assets Assets	5957301	USD
CY2012Q3	us-gaap	Assets Assets	5294851	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	5939370	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	5276476	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2039905	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4430740	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1513365	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1824141	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2390835	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	310776	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2039905	USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16666667	shares
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16666667	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16700000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7222636	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6674068	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86500000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7200000	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7222636	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6674068	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86500000	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7200000	shares
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	86657	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	80075	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1940119	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1463894	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1217234	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-989580	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19831896	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16	USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty	18991	USD
CY2012Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	637182	USD
CY2013Q1	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	3222	USD
CY2012Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	404	USD
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	917809	shares
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1		shares
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	917809	shares
CY2013Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	2317198	USD
CY2012Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	454381	USD
	us-gaap	Depreciation Depreciation	2899	USD
	us-gaap	Depreciation Depreciation	11713	USD
	us-gaap	Depreciation Depreciation	123743	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	44699	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-98005	USD
CY2013Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.31
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.25
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.17
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.17
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-26163	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-19180	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-36231	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	240776	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	628630	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	800848	USD
CY2012Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue		USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-25039	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-22143	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-56076	USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2013Q1	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2012Q1	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	28034	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1061038	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	850047	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	511605	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	510834	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	229704	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9011594	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2184627	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1463894	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1225874	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-985375	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19835628	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-175031	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	140867	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	422142	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	228272	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	4667	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	1307	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	24853	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	403870	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30802	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	564029	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	7509	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	16000	USD
CY2013Q1	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	9425	USD
CY2012Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	8867	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	24900	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1155956	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5957301	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5294851	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	469394	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	644425	USD
CY2013Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	239898	USD
CY2012Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	872413	USD
CY2013Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	228272	USD
CY2012Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	228272	USD
CY2013Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	987353	USD
CY2012Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	200311	USD
	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><!--StartFragment--> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 36.85pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">  </div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> a.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"> General:</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 8.1pt; text-align: left; TEXT-INDENT: 0pt"> Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. ("Hadasit") (the "First Agreement") to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, see also note 2a.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: -2.85pt; text-align: left; TEXT-INDENT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> In February 2013, the Company's common stock began trading on The Nasdaq Capital Market under the symbol ORMP.</font><br /> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary"), (together with the Company, "the Group").</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities" due to the fact that it has not generated any revenues from its operations.</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> Based on its current cash resources and commitments, and cash received in private offerings in the year ended August 31, 2012 and the six month period ended February 28, 2013 (see note 4b), the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.</div> <!--EndFragment--></div> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1450936	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16942875	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1750018	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1405536	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1915769	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2065590	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1075580	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12950970	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	122977	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	244508	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2184627	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1463894	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-1225874	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-985375	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20076404	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4478917	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-2769271	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-2760474	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-2977376	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-1561245	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-3344478	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1991669	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1406268	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1259830	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-940351	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20120786	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	122977	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5630	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4205	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax		USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8640	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4205	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	244508	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-50687	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax		USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-50687	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax		USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-50687	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	172218	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax		USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	53697	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax		USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	172218	USD
CY2012Q3	us-gaap	Other Liabilities Fair Value Disclosure OtherLiabilitiesFairValueDisclosure	637182	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	332002	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	29043	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	381666	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1331	USD
CY2013Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	32844	USD
CY2012Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9487	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	712382	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	139044	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	14528	USD
CY2013Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	66800	USD
CY2012Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7574	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	346202	USD
CY2013Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	99533	USD
CY2012Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	84642	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	628630	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1		USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	628630	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2013Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2012Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	434876	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	43111	USD
CY2013Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
CY2012Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	43111	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	3597	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	8226	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2129	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125612	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1862817	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	-961262	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	7766552	USD
CY2013Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	11626	USD
CY2012Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	6959	USD
CY2013Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	36406	USD
CY2012Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2307	USD
CY2013Q1	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	6637	USD
CY2012Q3	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	4740	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	66243	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	5428000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	114130	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	450000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	564130	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1869	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4768	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><!--StartFragment--> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 36.85pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">  </div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> d.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"> Reclassifications</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> Certain figures in respect of prior years have been reclassified to conform to the current year presentation.</div> <!--EndFragment--></div> </div>
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1450936	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	16595571	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	120000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	120000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1141622	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	894663	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	748996	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	710647	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10674316	USD
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2012Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20076404	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17891777	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	441084	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	83036	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5412371	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	5248009	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	3778013	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	3723916	USD
CY2010Q3	us-gaap	Stockholders Equity StockholdersEquity	830272	USD
CY2009Q3	us-gaap	Stockholders Equity StockholdersEquity	2746192	USD
CY2008Q3	us-gaap	Stockholders Equity StockholdersEquity	4593060	USD
CY2007Q3	us-gaap	Stockholders Equity StockholdersEquity	513131	USD
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	53700	USD
CY2013Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio StockholdersEquityNoteStockSplitConversionRatio	12	pure
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	77779	USD
CY2008	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	275000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2122981	USD
CY2008	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5784800	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3694212	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2944464	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	434876	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7018766	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5845784	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7212767	shares
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5848798	shares

Files In Submission

Name	View Source	Status
0001178913-13-001073-index-headers.html	Edgar Link	pending
0001178913-13-001073-index.html	Edgar Link	pending
0001178913-13-001073.txt	Edgar Link	pending
0001178913-13-001073-xbrl.zip	Edgar Link	pending
exhibit_31-1.htm	Edgar Link	pending
exhibit_31-2.htm	Edgar Link	pending
exhibit_32-1.htm	Edgar Link	pending
exhibit_32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
ormp-20130228.xml	Edgar Link	completed
ormp-20130228.xsd	Edgar Link	pending
ormp-20130228_cal.xml	Edgar Link	unprocessable
ormp-20130228_def.xml	Edgar Link	unprocessable
ormp-20130228_lab.xml	Edgar Link	unprocessable
ormp-20130228_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zk1312920.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2013 Q2 Form 10-Q Financial Statement

#000117891313001073 Filed on April 11, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2013 Q2 Form 10-Q Financial Statement

#000117891313001073 Filed on April 11, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp